The addition of nivolumab improved PFS, though OS benefits did not reach statistical significance.
← all excerpts
Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications.
1
—
—
The addition of nivolumab improved PFS, though OS benefits did not reach statistical significance.